scholarly journals Macrophage Stimulating Protein Enhances Hepatic Inflammation in a NASH Model

PLoS ONE ◽  
2016 ◽  
Vol 11 (9) ◽  
pp. e0163843 ◽  
Author(s):  
Jieyi Li ◽  
Dipanjan Chanda ◽  
Patrick J. van Gorp ◽  
Mike L. J. Jeurissen ◽  
Tom Houben ◽  
...  
2018 ◽  
Vol 19 (8) ◽  
pp. 2165 ◽  
Author(s):  
Su Lee ◽  
Min Nam ◽  
Da Lee ◽  
Jeen-Woo Park ◽  
Beom Kang ◽  
...  

The mechanisms underlying the progression to non-alcoholic steatohepatitis (NASH) remain to be elucidated. In the present study, we aimed to identify the proteins involved in the pathogenesis of liver tissue inflammation and to investigate the effects of silibinin, a natural polyphenolic flavonoid, on steatohepatitis. We performed comparative proteomic analysis using methionine and choline-deficient (MCD) diet-induced NASH model mice. Eighteen proteins were identified from the two-dimensional proteomic analysis, which are not only differentially expressed, but also significantly improved, by silibinin treatment. Interestingly, seven of these proteins, including keratin cytoskeletal 8 and 18, peroxiredoxin-4, and protein disulfide isomerase, are known to undergo GlcNAcylation modification, most of which are related to structural and stress-related proteins in NASH model animals. Thus, we primarily focused on how the GlcNAc modification of these proteins is involved in the progression to NASH. Remarkably, silibinin treatment alleviates the severity of hepatic inflammation along with O-GlcNAcylation in steatohepatitis. In particular, the reduction of inflammation by silibinin is due to the inhibition of the O-GlcNAcylation-dependent NF-κB-signaling pathway. Therefore, silibinin is a promising therapeutic agent for hyper-O-GlcNAcylation as well as NASH.


2010 ◽  
Vol 48 (01) ◽  
Author(s):  
G Kirovski ◽  
C Dorn ◽  
TS Weiss ◽  
D Schacherer ◽  
H Wobser ◽  
...  

2012 ◽  
Vol 50 (01) ◽  
Author(s):  
S Arndt ◽  
E Wacker ◽  
M Saugspier ◽  
C Dorn ◽  
C Hellerbrand ◽  
...  
Keyword(s):  

2019 ◽  
Author(s):  
J Remetic ◽  
V Mlitz ◽  
V Kunczer ◽  
H Scharnagl ◽  
T Stojakovic ◽  
...  

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1887-P
Author(s):  
SOPHIE A. MONTANDON ◽  
EMMANUEL SOMM ◽  
CLAUDIO DE VITO ◽  
FRANÇOIS R. JORNAYVAZ

2019 ◽  
Vol 19 (10) ◽  
pp. 782-795
Author(s):  
John W. Wright ◽  
Kevin J. Church ◽  
Joseph W. Harding

Pancreatic cancer (PC) ranks twelfth in frequency of diagnosis but is the fourth leading cause of cancer related deaths with a 5 year survival rate of less than 7 percent. This poor prognosis occurs because the early stages of PC are often asymptomatic. Over-expression of several growth factors, most notably vascular endothelial growth factor (VEGF), has been implicated in PC resulting in dysfunctional signal transduction pathways and the facilitation of tumor growth, invasion and metastasis. Hepatocyte growth factor (HGF) acts via the Met receptor and has also received research attention with ongoing efforts to develop treatments to block the Met receptor and its signal transduction pathways. Macrophage-stimulating protein (MSP), and its receptor Ron, is also recognized as important in the etiology of PC but is less well studied. Although the angiotensin II (AngII)/AT1 receptor system is best known for mediating blood pressure and body water/electrolyte balance, it also facilitates tumor vascularization and growth by stimulating the expression of VEGF. A metabolite of AngII, angiotensin IV (AngIV) has sequence homology with the “hinge regions” of HGF and MSP, key structures in the growth factor dimerization processes necessary for Met and Ron receptor activation. We have developed AngIV-based analogs designed to block dimerization of HGF and MSP and thus receptor activation. Norleual has shown promise as tested utilizing PC cell cultures. Results indicate that cell migration, invasion, and pro-survival functions were suppressed by this analog and tumor growth was significantly inhibited in an orthotopic PC mouse model.


Sign in / Sign up

Export Citation Format

Share Document